Dipòsit Digital de Documents de la UAB
Publicación
Artículo científico (JournalArticle)
Worse outcome and distinct mutational pattern in follicular lymphoma with anti-HBc positivity
Epidemiological studies have demonstrated the association between hepatitis B virus (HBV) infection and B-cell non-Hodgkin lymphoma (NHL), mainly for diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). We studied a cohort of 121 patients with FL for HBV infection status, clinical features, and gene mutational profile. Anti-HBc was detectable in 16 patients (13.2%), although all had undetectable HBV DNA. AntiHBcore (anti-HBc) cases presented with older age at diagnosis than anti-HBc cases (68.1 vs 57.2 years; P 5.007) and higher b2-microglobulin (56.3% vs 28.9%; P 5.04). All patients included in the study fulfilled criteria for treatment and received therapy with rituximab or rituximab-containing chemotherapy. There were no episodes of HBV reactivation or HBV hepatitis during treatment and/or maintenance. Remarkably, anti-HBc patients had significantly lower 10-year progression-free survival (PFS; 12.9% vs 58.3%; P,.0001) and overall survival (OS; 22.0% vs 86.2%; P,.0001), that remained at multivariate analysis. Gene mutational profiling of all cases showed that anti-HBc cases had higher incidence of ARID1A mutations and absence of EP300 mutations, 2 key epigenetic regulators in FL. Overall, our study shows that FL patients with resolved HBV infection have a worse outcome independently of other well-known clinical risk factors and a distinct gene mutational profile.
Proyecto:
Agència de Gestió d'Ajuts Universitaris i de Recerca 2017/SGR-205
,
Instituto de Salud Carlos III PI15/0459
,
Instituto de Salud Carlos III PI19/00034
HANDLE: https://ddd.uab.cat/record/270507, https://dx.doi.org/urn:doi:10.1182/bloodadvances.2021005316